ANN THEODORE FOUNDATION SARCOIDOSIS INHIBITOR OF MTOR (SIM) TRIAL

This initiative supports early Phase 2 clinical trials evaluating mTOR inhibitors' efficacy in treating cutaneous sarcoidosis, aiming to advance understanding of immunopathology in this rare disease and lay the groundwork for subsequent Phase 2b/3 or Phase 3 trials.